NEW YORK (GenomeWeb) – As the US market for genomics-based breast cancer recurrence testing becomes ever more competitive, companies are looking to gain an edge by demonstrating that their tests are better at predicting how patients fare over the long term and whether they will benefit from chemotherapy or can skip it.

While Genomic Health's Oncotype DX test, which analyzes expression of 21 genes, is the clear market leader, other players, like Agendia, are maneuvering to capture some of that space by pitting their tests against each other.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.